Clinical protocol
RTOG 0126: A Phase III Randomized Study of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer
NRG Oncology / RTOG
DoseLab summary
NRG Oncology's page for RTOG 0126, a randomized dose-escalation trial for localized prostate cancer.
Why this is useful
RTOG dose-escalation trial; cited by eviQ for the penile bulb mean-dose guideline. Protocol documents are available via the NCI CTSU, not directly on the NRG page.
Reference details
- Title
- RTOG 0126: A Phase III Randomized Study of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer
- Authors / organization
- NRG Oncology / RTOG
- Publication / protocol
- Protocol, RTOG 0126
- Version
- Pending verification
- Year
- 2014
- DOI
- Pending verification
- Disease sites
- Prostate
- Topics
- Prostate, Dose Constraints, RTOG, NRG, Protocols
- Fractionation context
- Conventional (dose escalation)
- Last reviewed by DoseLab
- Pending verification